NASDAQ:TMCI Treace Medical Concepts (TMCI) Stock Price, News & Analysis → We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How) (From Paradigm Press) (Ad) Free TMCI Stock Alerts $5.91 -0.20 (-3.27%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$5.80▼$6.0750-Day Range$4.17▼$13.0552-Week Range$3.92▼$26.56Volume886,781 shsAverage Volume878,056 shsMarket Capitalization$366.48 millionP/E RatioN/ADividend YieldN/APrice Target$12.21 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Treace Medical Concepts alerts: Email Address Treace Medical Concepts MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside106.7% Upside$12.21 Price TargetShort InterestBearish10.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 10 Articles This WeekInsider TradingAcquiring Shares$2.67 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.89) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.41 out of 5 starsMedical Sector248th out of 905 stocksSurgical & Medical Instruments Industry30th out of 97 stocks 4.0 Analyst's Opinion Consensus RatingTreace Medical Concepts has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageTreace Medical Concepts has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Treace Medical Concepts' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.35% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Treace Medical Concepts has recently increased by 49.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTreace Medical Concepts does not currently pay a dividend.Dividend GrowthTreace Medical Concepts does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMCI. Previous Next 3.9 News and Social Media Coverage News SentimentTreace Medical Concepts has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.Search Interest14 people have searched for TMCI on MarketBeat in the last 30 days. MarketBeat Follows15 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days. This is an increase of 1,400% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Treace Medical Concepts insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,665,822.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders24.43% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Treace Medical Concepts' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.89) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Treace Medical Concepts is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Treace Medical Concepts is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTreace Medical Concepts has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Treace Medical Concepts' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. About Treace Medical Concepts Stock (NASDAQ:TMCI)Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.Read More TMCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMCI Stock News HeadlinesJune 4, 2024 | insidertrades.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Director Acquires $151,250.00 in StockMay 30, 2024 | insidertrades.comInsider Buying: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director Buys 50,000 Shares of StockMay 24, 2024 | insidertrades.comInsider Buying: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director Purchases 12,100 Shares of StockMay 21, 2024 | insidertrades.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) CEO Purchases $556,000.00 in StockMay 14, 2024 | insidertrades.comInsider Buying: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director Purchases 25,000 Shares of StockJune 7 at 1:50 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCIJune 5 at 4:28 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCIJune 5 at 4:42 AM | americanbankingnews.comJames T. Treace Acquires 25,000 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) StockJune 5 at 1:56 AM | americanbankingnews.comBrokerages Set Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target at $12.21May 31, 2024 | americanbankingnews.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Director Purchases $253,500.00 in StockMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCIMay 28, 2024 | globenewswire.comTreace to Present at Truist Securities MedTech ConferenceMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCIMay 19, 2024 | 247wallst.comCEOs and Other Insiders Are Buying Shares of These 7 StocksMay 17, 2024 | msn.comUBS Downgrades Treace Medical Concepts (TMCI)May 17, 2024 | businesswire.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Treace Medical Concepts, Inc. (TMCI)May 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCIMay 16, 2024 | markets.businessinsider.comUnveiling 6 Analyst Insights On Treace Medical ConceptsMay 15, 2024 | finance.yahoo.comDirector Jane Kiernan Acquires 19,356 Shares of Treace Medical Concepts Inc (TMCI)May 14, 2024 | finance.yahoo.comDirector Richard Mott Acquires 120,000 Shares of Treace Medical Concepts Inc (TMCI)May 14, 2024 | finance.yahoo.comDirector Deepti Jain Acquires 25,000 Shares of Treace Medical Concepts Inc (TMCI)May 13, 2024 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comEarnings Update: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Just Reported And Analysts Are Trimming Their ForecastsMay 9, 2024 | msn.comMorgan Stanley Downgrades Treace Medical Concepts (TMCI)May 9, 2024 | msn.comBTIG Downgrades Treace Medical Concepts (TMCI)See More Headlines Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/07/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TMCI CUSIPN/A CIK1630627 Webwww.treace.com Phone904-373-5940FaxN/AEmployees516Year FoundedN/APrice Target and Rating Average Stock Price Target$12.21 High Stock Price Target$27.50 Low Stock Price Target$5.50 Potential Upside/Downside+106.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,530,000.00 Net Margins-27.93% Pretax Margin-27.93% Return on Equity-39.66% Return on Assets-22.24% Debt Debt-to-Equity Ratio0.42 Current Ratio3.98 Quick Ratio3.22 Sales & Book Value Annual Sales$187.12 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book2.64Miscellaneous Outstanding Shares62,010,000Free Float46,859,000Market Cap$366.48 million OptionableOptionable Beta0.18 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. John T. Treace (Age 52)CEO, Founder & Director Comp: $1.09MMr. Mark L. Hair CPA (Age 54)Chief Financial Officer Comp: $599.7kMr. Aaron J. Berutti (Age 45)Senior Vice President of Sales Comp: $484.22kMr. Terry W. Lubben (Age 59)Senior Vice President of Operations Mr. Taylor EricksonChief Information & Security OfficerMs. Julie D. Dewey (Age 63)Chief Communications & Investor Relations Officer Mr. Scot M. Elder J.D. (Age 49)Chief Legal & Compliance Officer and Corporate Secretary Mr. Nathan MinnichSenior Vice President of MarketingMr. Daniel E. Owens (Age 52)Chief Human Resources Officer Dr. Sean F. Scanlan Ph.D. (Age 42)Chief Innovation Officer More ExecutivesKey CompetitorsOrganogenesisNASDAQ:ORGOSmileDirectClubNASDAQ:SDCAlphatecNASDAQ:ATECMiMedx GroupNASDAQ:MDXGAtriCureNASDAQ:ATRCView All CompetitorsInsiders & InstitutionsJames T TreaceBought 25,000 shares on 5/31/2024Total: $151,250.00 ($6.05/share)James T TreaceBought 50,000 shares on 5/28/2024Total: $253,500.00 ($5.07/share)Richard W MottBought 12,100 shares on 5/22/2024Total: $60,379.00 ($4.99/share)John T TreaceBought 100,000 shares on 5/17/2024Total: $556,000.00 ($5.56/share)Grandeur Peak Global Advisors LLCBought 34,075 shares on 5/16/2024Ownership: 0.089%View All Insider TransactionsView All Institutional Transactions TMCI Stock Analysis - Frequently Asked Questions Should I buy or sell Treace Medical Concepts stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TMCI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMCI, but not buy additional shares or sell existing shares. View TMCI analyst ratings or view top-rated stocks. What is Treace Medical Concepts' stock price target for 2024? 7 Wall Street analysts have issued 12 month price targets for Treace Medical Concepts' shares. Their TMCI share price targets range from $5.50 to $27.50. On average, they predict the company's stock price to reach $12.21 in the next twelve months. This suggests a possible upside of 106.7% from the stock's current price. View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts. How have TMCI shares performed in 2024? Treace Medical Concepts' stock was trading at $12.75 at the start of the year. Since then, TMCI stock has decreased by 53.6% and is now trading at $5.91. View the best growth stocks for 2024 here. Are investors shorting Treace Medical Concepts? Treace Medical Concepts saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,550,000 shares, an increase of 49.7% from the April 30th total of 3,040,000 shares. Based on an average daily volume of 994,100 shares, the short-interest ratio is currently 4.6 days. Currently, 10.4% of the shares of the company are short sold. View Treace Medical Concepts' Short Interest. When is Treace Medical Concepts' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our TMCI earnings forecast. How were Treace Medical Concepts' earnings last quarter? Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30). The company earned $51.11 million during the quarter, compared to analyst estimates of $49.07 million. Treace Medical Concepts had a negative net margin of 27.93% and a negative trailing twelve-month return on equity of 39.66%. The company's revenue was up 21.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.23) earnings per share. What guidance has Treace Medical Concepts issued on next quarter's earnings? Treace Medical Concepts issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $201.0 million-$211.0 million, compared to the consensus revenue estimate of $222.8 million. When did Treace Medical Concepts IPO? Treace Medical Concepts (TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers. Who are Treace Medical Concepts' major shareholders? Treace Medical Concepts' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.97%), William Blair Investment Management LLC (3.77%), TimesSquare Capital Management LLC (2.24%), Wealth Enhancement Advisory Services LLC (0.39%), Oak Ridge Investments LLC (0.20%) and GSA Capital Partners LLP (0.11%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, Deepti Jain, F Barry Bays, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie. View institutional ownership trends. How do I buy shares of Treace Medical Concepts? Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TMCI) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Treace Medical Concepts With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.